CAD Middle East Pharmaceutical Industries/ Kingdom of Saudi Arabia
The Company was established in 2006 with a capital of SAR 73,000,000, equivalent to KWD 5,496,900. ACDIMA owns 25% in the capital of this Company, equivalent to KWD 2,768,900. The financial statements showed that the project generated losses in the financial year 2014 with the amount of SAR 52,448,948, equivalent to KWD 4,091,018. The production program of the Company is designed to manufacture (21) active raw materials. The engineering and pharmaceutical study has designed the factory of this Company so that its production capacity of the active raw materials will nearly be 118 tons / year. This project is one of the pilot projects in the Arab World for producing active raw pharmaceuticals. As Arab pharmaceutical factories still rely on importing their demanded requirements of these materials from abroad; the products of the project will be marketed inside and outside the Arab Countries. The production of this Company will support the Arab pharmaceutical industry with active raw materials included in the production program of the project. CAD quality control factories started to work since November, 2013. A license was also granted for the factory by the Saudi Food and Drug Authority.